Cantargia AB (publ) (STO:CANTA)
Sweden flag Sweden · Delayed Price · Currency is SEK
2.942
-0.238 (-7.48%)
May 22, 2026, 5:29 PM CET

Cantargia AB Company Description

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases.

The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis.

It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Otsuka Pharmaceutical Co., Ltd for the clinical IL1RAP targeting antibody CAN10 as well as the preclinical antibody 3G5; and BioWa Inc., granted a nonexclusive license to use the technology platform POTELLIGENT® for the manufacture of the drug candidate nadunolimab.

Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.

Cantargia AB (publ)
CountrySweden
Founded2009
IndustryBiotechnology
SectorHealthcare
Employees22
CEOHilde Steineger

Contact Details

Address:
Ideon Gateway
Lund, 223 63
Sweden
Phone46 4 62 75 62 60
Websitecantargia.com

Stock Details

Ticker SymbolCANTA
ExchangeNasdaq Stockholm
Fiscal YearJanuary - December
Reporting CurrencySEK
ISIN NumberSE0006371126
SIC Code2836

Key Executives

NamePosition
Dr. Hilde Hermansen Steineger M.Sc., MSc, Ph.D.Chief Executive Officer
Thoas Fioretos M.D., Ph.D.Founder and Scientific Advisor
Marcus JäråsFounder and Scientific Advisor
Kjell SjöströmFounder
Patrik RenbladChief Financial Officer
Dr. David LibergChief Scientific Officer
Nina ValkamaExecutive Assistant of Administration and Finance
Antonius BerkienChief Business Officer
Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D.Chief Medical Officer
Johanna ChristensenFinancial Controller